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Background: Actinic keratoses (AKs) are skin lesions primarily caused by ultraviolet (UV) exposure. They
are precancerous lesions and can develop into non-melanoma skin cancer. Exposure to UV radiation leads to
the development of AKs by several mechanisms. UV radiation damages cellular DNA, depletes cellular energy
levels, and suppresses the immune system. Nicotinamide is a form of vitamin B3. Topical nicotinamide
increases cellular energy levels and protects against immunosupression in humans. The question arises, could
oral nicotinamide mitigate the harmful effects of UV radiation, and be useful in the reduction of AKs?
Methods: An exhaustive literature search was conducted using MEDLINE - Ovid, Web of Science, and
Google Scholar. The search terms nicotinamide and actinic keratosis were used. Applicable articles were
assessed for quality using the Grading of Recommendations, Assessment, Development, and Evaluation
(GRADE).
Results:Two studies met eligibility criteria and were included. Both were randomized, controlled, double-
blinded trials. One trial included two cohorts, with different doses of nicotinamide used. Cohort 1 found that
the number of AKs were 35% less in the nicotinamide group at 2 months (95% confidence interval (CI):
23-45%; p
Conclusion: The two studies reviewed demonstrated a reduction in AKs in patients taking oral nicotinamide.
Providers should consider oral nicotinamide supplementation in patients with sun-damaged skin. Further
research is needed to explore the action of nicotinamide on the prevention of AKs and NMSC.
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Abstract   
 
Background: Actinic keratoses (AKs) are skin lesions primarily caused by ultraviolet (UV) 
exposure. They are precancerous lesions and can develop into non-melanoma skin cancer. 
Exposure to UV radiation leads to the development of AKs by several mechanisms. UV radiation 
damages cellular DNA, depletes cellular energy levels, and suppresses the immune system. 
Nicotinamide is a form of vitamin B3. Topical nicotinamide increases cellular energy levels and 
protects against immunosupression in humans. The question arises, could oral nicotinamide 
mitigate the harmful effects of UV radiation, and be useful in the reduction of AKs?  
   
Methods: An exhaustive literature search was conducted using MEDLINE - Ovid, Web of 
Science, and Google Scholar. The search terms nicotinamide and actinic keratosis were used. 
Applicable articles were assessed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE). 
 
Results: Two studies met eligibility criteria and were included. Both were randomized, 
controlled, double-blinded trials. One trial included two cohorts, with different doses of 
nicotinamide used. Cohort 1 found that the number of AKs were 35% less in the nicotinamide 
group at 2 months (95% confidence interval (CI): 23-45%; p<0.0001) and at 4 months (95% 
confidence interval (CI): 18-48%; p=0.0006). Cohort 2 found that the number of AKs were 15% 
less in the nicotinamide group at 2 months (95% confidence interval (CI): 0-28%; p=0.046) and 
29% less at 6 months (95% confidence interval (CI): 11-44%; p=0.005). In the second study, the 
number of AKs were 11% lower in the nicotinamide group at 3 months (p=0.01), 14% lower at 6 
months (p<0.001), 20% lower at 9 months (p<0.001), and 13% lower at 12 months (p=0.001). 
  
Conclusion: The two studies reviewed demonstrated a reduction in AKs in patients taking oral 
nicotinamide. Providers should consider oral nicotinamide supplementation in patients with sun-
damaged skin. Further research is needed to explore the action of nicotinamide on the prevention 
of AKs and NMSC. 
 
Keywords: Nicotinamide and actinic keratoses  
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BACKGROUND 
Actinic keratoses (AKs) are skin lesions primarily caused by ultraviolet (UV) exposure. 
They are classified as dysplastic keratiocytic lesions and can have assorted presentations, but 
often appear as plaques or papules on an erythematous base. Actinic keratoses develop most 
commonly on chronically sun-exposed areas such as the scalp, face, neck, and upper extremity. 
They are precancerous lesions and can develop into non-melanoma skin cancer (NMSC), most 
likely squamous cell carcinoma (SCC).1 Non-melanoma skin cancer is the most commonly 
diagnosed cancer in the United States, and the incidence is increasing.2  
Primary prevention of NMSC includes wearing protective clothing, using sunscreen, and 
sun avoidance. More specifically, using sunscreen can help reduce the number of AKs and 
prevent SCC.3 The rate of sunscreen use among adults is low. Only 18.1% of men and 42.6% of 
women report regular use of sunscreen on the face. Both men and women reported even less 
sunscreen use on other commonly sun-exposed skin.4 With the continuing increase in skin 
cancer, and the non-adherence to current preventative measures, there needs to be additional 
tools for the prevention of these diseases. 
Exposure to UV radiation leads to the development of AKs by several mechanisms. UV 
radiation damages cellular DNA, resulting in genetic mutation and the expression of abnormal 
cells.5 UV radiation also depletes cellular ATP levels. With low energy levels, a cell cannot 
repair damage.6 Finally, UV radiation suppresses the immune system by altering the function of 
antigen presenting cells, T-cells, natural killer cells and cytokine function.7 Organ transplant 
patients, who are on chronic immunosuppressant drugs, are significantly more likely to develop 
AKs and skin cancers.8 
Nicotinamide is an amide of vitamin B3 and has been used in the treatment of various 
skin conditions such as acne vulgaris.9 Nicotinamide is safe and well tolerated. Unlike niacin, 
nicotinamide lacks the vasodilatory effects that cause flushing and hypotension.10 Nicotinamide 
is a precursor of NAD+ and is needed for ATP production. Sivapirabu et al11 found topical 
nicotinamide to increase cellular energy levels and protect against immunosupression in humans. 
The question arises, could oral nicotinamide mitigate the harmful effects of UV radiation, and be 
useful in the reduction of AKs? Specifically, does oral nicotinamide reduce actinic keratoses in 
adults with sun-damaged skin? 
METHODS 
An exhaustive literature search was conducted using the following search engines: 
MEDLINE - Ovid, Web of Science, and Google Scholar. The search terms nicotinamide and 
actinic keratosis were used. Inclusion criteria required human studies and studies in the English 
language. Trials that used a topical application of nicotinamide were excluded. Applicable 
articles were assessed for quality using the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE).12 
RESULTS 
The initial literature search resulted in 8 articles. Screening using the eligibility criteria 
narrowed the results to 2 articles.13, 14 Both articles were randomized controlled clinical trials.  
Surjana et al  
This study13 was published in 2012 and was a randomized, controlled, double-blinded 
trial. The authors were interested if oral nicotinamide could reduce the number of AKs in 
participants with UV damaged skin. This article consisted of two separate cohorts. Cohort 1 was 
conducted from June-October 2009. Groups received 500 mg of nicotinamide twice daily or a 
matched placebo. Cohort 2 was conducted from August-November 2010. Groups received either 
500 mg of nicotinamide once daily or a matched placebo. The primary endpoint of both cohorts 
was the number of AKs at 4 months. The secondary endpoint was the number of new skin 
cancers (BCC and SCC) developed during the 4-month study.13 
Participants were recruited from the Royal Prince Hospital Dermatology Clinics in 
Sydney, Australia. Included participants had a minimum of 4 palpable AKs in the treatment areas 
(face, scalp, and upper extremities) and were required to be healthy and immune-competent. The 
authors did not elaborate on the eligibility criteria any further in the published article. The 
Australian New Zealand Clinical Trials Registry15 was queried for additional information. Men 
and women 18 years or older were eligible to participate. Exclusion criteria were pregnancy or 
breastfeeding, the use of immunosuppressive or photosensitizing agents, nicotinamide or other 
vitamin supplement use, dermatitis in the treatment areas, liver disease, or carbamazepine use. 
After meeting criteria, 35 participants were randomized into cohort 1 and 41 participants were 
randomized into cohort 2.13 
The treatment allocation sequence was computer generated by an author using a 
permuted block method with a block size of six. Randomization occurred in a 1:1 ratio to receive 
either 500 mg of nicotinamide (Nature’s Own) or a matched placebo (Australian Custom 
Pharmaceuticals). Participants remained blinded to their treatment allocation throughout the 
study. Before randomization, participants underwent a complete skin check, and were advised to 
wear sunscreen daily during the trial. Any unused drug was returned at the visits to be counted 
and recorded for compliance.13 
A blinded author identified the AKs by palpation and observation at the baseline, the 2- 
month visits, and the 4-month visits. The authors analyzed the data under the intention to treat 
principle. The AK data was skewed to the right, and required a natural log transformation. Using 
an analysis of covariance adjusting for baseline AK number, the relative difference between the 
groups was calculated. Cohort 1 found that the number of AKs were 35% less in the 
nicotinamide group at 2 months (95% confidence interval (CI): 23-45%; p<0.0001) and at 4 
months (95% confidence interval (CI): 18-48%; p=0.0006). Cohort 2 found that the number of 
AKs were 15% less in the nicotinamide group at 2 months (95% confidence interval (CI): 0-
28%; p=0.046) and 29% less at 6 months (95% confidence interval (CI): 11-44%; p=0.005). 
Compliance in taking the tablets was calculated at 94-98% for both cohorts. One patient 
experienced an adverse event (AE), which was nausea while concomitantly taking aspirin.13    
The investigators concluded that nicotinamide is effective at reducing the number of AKs 
in participants compared to placebo. Limitations of the study included the short duration and 
small sample size. The first author did the AK assessments and new AKs were not confirmed 
histologically. Sunscreen use was encouraged, but compliance not tracked.  
Chen et al  
This study14 was published in 2015 and was a randomized, controlled, double-blinded 
trial. The authors were interested if oral nicotinamide could reduce the number of new NMSCs 
and AKs in patients with UV damaged skin. Treatment was either 500 mg of nicotinamide twice 
daily or a matched placebo for 12 months (both provided by Insolar, Blackmores). The primary 
endpoint was the number of new, confirmed NMSCs. The secondary endpoint included the 
number of new BCCs, SCCs, and AKs, and the safety profile of nicotinamide. The authors also 
looked at oral nicotinamide’s effect on and cognitive functioning and epidermal water loss.14  
Men and women 18 years or older with at least 2 NMSCs in the last 5 years were 
recruited from 2 hospitals in Sydney, Australia (Royal Prince Alfred and Westmead). Exclusion 
criteria were immunosupression, pregnancy or breastfeeding, impaired liver or kidney function, 
active peptic ulcer disease, recent MI, and hypotension. Genetic skin cancer syndromes, a large 
area of skin cancer, and use of nicotinamide, oral retinoids, or other treatment for AK in the last 
4 weeks was also exclusionary. Participants with a history of metastatic cancer, invasive 
melanoma, or an internal malignancy in the last 5 years were also excluded. After meeting 
criteria, 386 participants were randomized. Daily sunscreen use was instructed. Unused drug was 
returned at each visit to be counted and recorded for compliance.14 
Randomization was done centrally in a 1:1 ratio with stratification according to a 5-year 
history of NMSC (≤ 6 or >6 lesions), sex and study site. A blinded author at each site identified 
the AKs by palpation and observation at the baseline, at 3-month intervals. Treatment areas 
consisted of the face, scalp, forearms, and hands. A blinded histopathologist confirmed new 
lesions. The authors analyzed the data under the intention to treat principle using a mixed-effects 
model for repeated measures. The repeated measures included study group, center, baseline 
value, time point, and interaction between time and study group. The number of AKs was 11% 
lower in the nicotinamide group at 3 months (p=0.01), 14% lower at 6 months (p<0.001), 20% 
lower at 9 months (p<0.001), and 13% lower at 12 months (p=0.001). The median rate of 
compliance with treatment over the 12 months was 96% in the nicotinamide group and 94% in 
the placebo group. Rate of sunscreen use was higher in the placebo group than the nicotinamide 
group throughout the study, with significant differences at 6 months (58% vs 47% p=0.02) and 9 
months (59% vs 48% p=0.03). No significant differences in AEs was found between the two 
groups.14 
Investigators concluded that nicotinamide is effective at reducing the number of AKs in 
patients compared to placebo. A limitation to the study is that two authors did the AK 
assessments, and there is no test for inter-rater reliability. 
DISCUSSION 
The two studies13, 14 reviewed demonstrated a reduction in AKs in patients taking oral 
nicotinamide compared to placebo. The magnitude of the reduction was noticeably greater in the 
Surjana et al study.13 Both studies found nicotinamide to be well tolerated and safe. Both studies 
monitored blood counts, renal and kidney function, with no significant changes found between 
the treatment or placebo group.  
In analyzing the current evidence, there are some limitations that need to be addressed. 
Both studies were conducted by a similar group of investigators in Sydney, Australia. Three of 
the five authors from the Surjana et al study13 were represented in the Chen et al study.14 The 
body of research about this clinical question is quite limited; these are the only two currently 
published clinical trials. This raises the possibility of publication bias.  
As for detection of the primary outcome, palpation and observation is often used to 
diagnose AKs. A biopsy is preformed if the diagnosis is unclear or to rule out NMSC. AKs can 
have many presentations leading to difficulty in diagnosis. Weinstock et al16 found AK counts 
varied widely between dermatologists when looking at a single participant. Counting AKs was 
deemed an unreliable approach. Both studies reviewed here used palpation and observation as 
the primary method of assessing AKs. The Chen et al study14 histologically confirmed any new 
AKs, but had different authors at each site completing the AK counts, potentially introducing 
bias. Both studies acknowledged sunscreen use as a prognostic factor in the reduction of AKs. 
The Surjana et al study13 encouraged participants to use sunscreen daily, but did not track 
compliance.  
In the Surjana et al study,13 the sample size was quite small, and the participants had a 
large variation in the number of AKs at baseline, resulting in skewed data and large confidence 
intervals. The duration of the study was also quite short. In the Chen et al study,14 the confidence 
intervals were also quite wide. The inclusion criteria for this study focused on NMSC, not AKs. 
The range of AKs at baseline was 0-205 for the nicotinamide group and 0-214 for the placebo 
group, likely contributing to the lack of precision.  
The development of new NMSC was also explored as an endpoint in these studies. Chen 
et al14 found the rate of new NMSC was significantly lower at 12 months with nicotinamide than 
with placebo (relative difference=23%, p=0.02). This suggests nicotinamide may have a broader 
application in preventing new NMSC and in chemoprevention, but further research is needed to 
explore this topic. 
CONCLUSION 
Actinic keratoses are precancerous lesions that can progress to NMSC. The incidence of 
skin cancer is increasing, and current preventative measures show low compliance. The research 
reviewed found oral nicotinamide reduced the number of AKs versus placebo in participants 
with UV damaged skin. Providers should consider oral nicotinamide supplementation in this 
subset of patients due to its safety and likely efficacy. Further research is needed to explore the 
action of nicotinamide on the prevention of AKs and NMSC. 
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